# PROMUS Element Plus US Post-Approval Study

Study · id `cardio:ct-nct01589978` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01589978](<https://clinicaltrials.gov/study/NCT01589978>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01589978

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2681 participants.

## Technical summary

Registry record NCT01589978. Allocation not applicable; no masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2016-05-03.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2681 participants (enrolled count; ClinicalTrials.gov record NCT01589978, source copy `cardio:ctgov-nct01589978-2018-07-26`, retrieved 2026-10-26)
- Start date: 2012-05 (registry gives no type) (ClinicalTrials.gov record NCT01589978, source copy `cardio:ctgov-nct01589978-2018-07-26`, retrieved 2026-10-26)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01589978, source copy `cardio:ctgov-nct01589978-2018-07-26`, retrieved 2026-10-26)
- Completion: 2018-06 (actual) (ClinicalTrials.gov record NCT01589978, source copy `cardio:ctgov-nct01589978-2018-07-26`, retrieved 2026-10-26)
- Results first posted: 2016-05-03 (ClinicalTrials.gov record NCT01589978, source copy `cardio:ctgov-nct01589978-2018-07-26`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01589978, source copy `cardio:ctgov-nct01589978-2018-07-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01589978-2018-07-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: PROMUS Element Plus US Post-Approval Study
- Condition: Coronary Artery Disease
- Intervention (Device): PROMUS Element Plus Coronary Stent System
- Intervention (Drug): Aspirin
- Intervention (Drug): P2Y12 antagonist
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: e06cc35bd8d2d3b5fc86786217da0b8646ae56c413de64901f9e6da407997667
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
